| intervention | Study/author/year | RVO type | N0. of patients | Duration | Vision outcome |
| Laser photocoagulation | BVOS Group 1984 [24] | BRVO | Laser = 43 Control = 35 | 3 yrs. | Laser: 65% gained ≥ 2 line Control: 37% gained ≥ 2 line |
| Ranibizumab | BRAVOCampochiaro et al., 2010 [43] BRAVO Brown et al., 2011 [58] | BRVO | RBZ 0.5 mg = 131 RBZ 0.3 mg = 134 Control = 132 | 1 yr with primary endpoint at 6 mo | 6-mo outcomes: RBZ 0.5 mg: +18.3 letters; 61.1% gained ≥3 lines, RBZ 0.3 mg: +16.6 letters; 55.2% gained ≥3 lines Sham: +7.3 letters; 28.8% gained ≥3 lines |
| Ranibizumab | CRUISE 2010 Brown et al., 2010 [44] | CRVO | RBZ 0.5 mg = 130 RBZ 0.3 mg = 132 Control = 130 | 6 mo | 15-letter gain in ~17%, 46%, and 47% in sham, 0.3 mg, and 0.5 mg ranibizumab groups, respectively. |
| Bevacizumab | Epstein et al., 2012 [40] [41] | CRVO | IVB 2 mg = 30 Control = 30 | 6 mo | 15-letter gain in 60% of bevacizumab vs. 20% of sham eyes |
| Aflibercept | VIBRANTCampochiaro et al., 2015 [46] VIBRANT Clark et al., 2016 [47] | BRVO | IAI 2 mg = 91 Laser = 92 | 24-week primary endpoint, 1 yr study | 24-wk results: IAI: +17.0 letters, 52.7% gained ≥3 lines, Laser: +6.9 letters, 26.7% gained ≥3 lines, 52-wkresults: IAI: +17.1 letters, 57.1% gained ≥3 lines, Laser/IAI: +12.2 letters, 41.1% gained ≥3 or more lines |
| Aflibercept | COPERNICUS Brown et al., 2013 [48] | CRVO | VTE 2 mg = 115 Control = 74 | 6 mo | 15-letter gain in 56% of VTE eyes vs. 12% sham |
| Aflibercept | GALILEO Korobelnik et al., 2013 [49] | CRVO | VTE 2 mg = 106 Control = 71 | 52 weeks | 15-letter gain in 60% of VTE eyes vs. 32.4% in sham |
| Pegaptanib sodium | Wroblewski et al., 2009 [51] | CRVO | Pegaptanib 0.3 mg = 33 Pegaptanib 1.0 mg = 33 Control = 32 | 30 weeks | 36% and 39% of eyes treated with 0.3 mg and 1 mg pegaptanib gained ≥15 letters vs. 28% of sham |
| Triamcinolone Acetonide | SCORE Scott et al., 2009 [31] | BRVO | IVTA 4 mg = 138 IVTA 1 mg = 136 Laser = 137 | 12-mo primary endpoint 36 mo total | IVTA 4 mg: +4.0 letters, 27.2% gained ≥3 Lines, IVTA 1 mg: +5.7 letters; 25.6% gained ≥3 lines Laser: +4.2 letters, 28.9% gained ≥3 lines |
|
| SCORE Ip et al. 2009 [30] | CRVO | Total = 271, IVTA 4 mg, 1 mg vs Control | 12 mo | 15-letter gain in ~7%, 27%, and 26% for observation, 1 mg, and 4 mg groups, respectively |
| Dexamethasone | GENEVA Haller et al., 2010 [34] [35] | BRVO & CRVO | DEX 0.7 mg = 427, DEX 0.35 mg = 414, Control = 426, | 6 mo | 15-letter gain in 23%, 41%, and 40% for observation, 0.35 mg, and 0.7 mg DEX groups, respectively |